Effect of antibiotics on Tyzzer's disease.
D000666:Amphotericin B / Q000627:therapeutic use; D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001375:Azaguanine / Q000627:therapeutic use; D002509:Cephaloridine / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003523:Cycloserine / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D007612:Kanamycin / Q000627:therapeutic use; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014756:Viomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D008937:Mitomycins; D010406:Penicillins; D011113:Polymyxins; D007612:Kanamycin; D004917:Erythromycin; D002701:Chloramphenicol; D000667:Ampicillin; D000666:Amphotericin B; D003520:Cyclophosphamide; D003523:Cycloserine; D013752:Tetracycline; D002509:Cephaloridine; D001375:Azaguanine; D013307:Streptomycin; D014756:Viomycin; D003091:Colistin